Recent Advances in Multiple Myeloma: Insights from Experts at University of Pennsylvania : Episode 5
Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma
Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.
EP: 1.Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 2.Recent Updates on Treatment Options for Patients With Transplant-Eligible NDMM
EP: 3.Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 4.Consolidation and Maintenance Therapy in Transplant-Eligible NDMM
Now Viewing
EP: 5.Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 6.Selecting Induction Therapy for Patients With High-Risk Transplant-Eligible NDMM
EP: 7.Transplant-Eligible NDMM: Optimizing Therapy for Efficacy and Tolerability
EP: 8.Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
EP: 9.Selecting the Optimal Therapy for Patients With Transplant-Ineligible NDMM
EP: 10.Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM
EP: 11.University of Pennsylvania Experts Discuss Treatment Options in Transplant-Eligible and -Ineligible Newly Diagnosed Multiple Myeloma
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
